A combination of p53-activating APR-246 and phosphatidylserine-targeti | BCTT @DovePress https://t.co/3zemeGIZUZ
RT @MizzouBioMed: On the ninth day of the @MizzouBioMed holiday publication spectacular, Dr. Hyder's lab continues its excellent work tryin…
RT @MizzouBioMed: On the ninth day of the @MizzouBioMed holiday publication spectacular, Dr. Hyder's lab continues its excellent work tryin…
On the ninth day of the @MizzouBioMed holiday publication spectacular, Dr. Hyder's lab continues its excellent work trying to treat #breastcancer in @DovePress . https://t.co/mofscCp9WE
A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts | BCTT @DovePress https://t.co/zAN5XL8h8O
Breast tumor growth could be effectively controlled by simultaneous targeting of mtp53 protein and tumor blood vessels in mtp53-expressing cancers. https://t.co/XQ8Td52Y4j https://t.co/cQ7LNxTlML